News Release

Cardiovascular risk biomarkers in inflammaging

“Here, we advocate for a more comprehensive biomarker-based approach to CV risk that incorporates two distinct dimensions”

Peer-Reviewed Publication

Impact Journals LLC

Integrating cardiovascular risk biomarkers in the context of inflammaging

image: 

Figure 1. Integration of inflammaging biomarkers with organ function markers. This figure illustrates the interplay between biomarkers of inflammaging and markers of organ function. Inflammaging is characterized by chronic, low-grade inflammation and can be assessed using markers such as high-sensitivity C-reactive protein (hs-CRP), cytokines, cellular senescence indicators, oxidative stress, and immune profiles. Both modifiable (e.g., lifestyle, diet, smoking) and non-modifiable (e.g., genetics, sex, age) factors influence inflammaging, which contributes to age-related organ decline. Organ function is evaluated using biomarkers such as blood glucose, BMI, kidney function (eGFR), lung function (FVC/FEV1), and arterial blood pressure. The inclusion of cardiac biomarkers such as high-sensitivity cardiac troponin (hs-cTn) and natriuretic peptides (BNP, NT-proBNP) is crucial for assessing cardiovascular risk and dysfunction. These markers act as early indicators of subclinical cardiac damage and predictors of future cardiovascular events. Incorporating these cardiac biomarkers into preventive care enhances risk stratification and informs therapeutic strategies to address residual inflammatory risk, a key factor in cardiovascular disease.

view more 

Credit: 2024 Sabbatinelli et al.

“Here, we advocate for a more comprehensive biomarker-based approach to CV risk that incorporates two distinct dimensions.”

BUFFALO, NY- October 29, 2024 – A new editorial was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 19 on October 14, 2024, entitled “Integrating cardiovascular risk biomarkers in the context of inflammaging.”

Cardiovascular diseases (CVD) remain the leading cause of death worldwide, accounting for nearly one-third of all global mortalities. Risk assessment for CVD has traditionally focused on well-known factors linked to atherosclerosis, including demographics, lifestyle choices like smoking and physical activity, and conditions such as diabetes, hypertension, and obesity. Biomarkers, such as non-HDL cholesterol, have also played a key role in identifying those at risk.

However, significant residual cardiovascular risk persists despite managing these established risk factors, suggesting additional, unaddressed contributors to cardiovascular health.

In their paper, researchers Jacopo Sabbatinelli, Matilde Sbriscia, Fabiola Olivieri, and Angelica Giuliani from Università Politecnica delle Marche and IRCCS INRCA in Ancona, Italy, explore how integrating specific cardiovascular biomarkers could help assess this residual inflammatory risk, particularly in the context of aging-related inflammation, or “inflammaging.” The biomarkers investigated—high-sensitivity C-reactive protein (hs-CRP), high-sensitivity cardiac troponin (hs-cTn), and natriuretic peptides—serve as valuable indicators of both inflammatory burden and early cardiovascular risk.

In conclusion, the authors demonstrate that combining markers of chronic inflammation with cardiac health indicators offers a more complete understanding of cardiovascular risk and reveals the impact of aging-related inflammation, or "inflammaging," on heart health. Researchers suggest that this approach opens new avenues for targeted interventions in aging populations.

Read the full paper: DOI: https://doi.org/10.18632/aging.206136

Corresponding Author: Jacopo Sabbatinelli - j.sabbatinelli@staff.univpm.it

Keywords: aging, cardiovascular disease, inflammaging, cardiac biomarkers, residual inflammatory risk

Click here to sign up for free Altmetric alerts about this article.

About Aging:

The journal Aging aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)

Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed CentralWeb of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

Please visit our website at www.Aging-US.com​​ and connect with us:

Click here to subscribe to Aging publication updates.

For media inquiries, please contact media@impactjournals.com.

Aging (Aging-US) Journal Office
6666 E. Quaker St., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 1


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.